DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2007/0213382 A1 Rudy Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2007/0213382 A1 Rudy Et Al US 20070213382A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0213382 A1 Rudy et al. (43) Pub. Date: Sep. 13, 2007 (54) 2-METHYLTHIAZOLIDINE-2, Publication Classification 4-DICARBOXYLIC ACID-CONTAINING COMBINATION PREPARATIONS (51) Int. Cl. A6II 3/426 (2006.01) (76) Inventors: Susilo Rudy, Koln (DE); Eberhard A6II 38/19 (2006.01) Amtmann, Heidelberg (DE) A6II 38/09 (2006.01) A6II 38/16 (2006.01) Correspondence Address: A6II 38/18 (2006.01) J C PATENTS, INC. A6II 3 L/704 (2006.01) 4 VENTURE, SUITE 250 A61K 3 1/7048 (2006.01) IRVINE, CA 92.618 (US) A6II 3/522 (2006.01) A61K 31/7072 (2006.01) (21) Appl. No.: 11/568,506 A6II 3/53 (2006.01) A61K 31/4745 (2006.01) (22) PCT Fed: May 2, 2005 (52) U.S. Cl. .............................. 514/365: 514/34: 514/27; 514/492; 514/109; 514/8: 514/283; (86) PCT No.: PCT/DEOS/OO810 514/12: 514/171; 514/449; 424/85.1; 424/649: 424/155.1; S 371(c)(1), 424/94.63: 514/49; 514/263.34; (2), (4) Date: Oct. 30, 2006 514/251; 514/269; 514/410; Related U.S. Application Data 514/15 (57) ABSTRACT (60) Provisional application No. 60/569,570, filed on May The invention relates to a combination preparation of 2-me 10, 2004. thylthiazolidine-2,4-dicarboxylic acid and/or physiologi (30) Foreign Application Priority Data cally acceptable salts thereof and at least one cytotoxic and/or cytostatic compound as well as the use of these May 3, 2004 (DE).......................... 10-2004-021-658.4 combination preparations for the treatment of cancer. US 2007/0213382 A1 Sep. 13, 2007 2-METHYLTHIAZOLIDINE-2,4-DICARBOXYLIC 0010 Thus, the present invention relates to combination ACID-CONTAINING COMBINATION preparations which comprise 2-methylthiazolidine-2,4-di PREPARATIONS carboxylic acid and/or physiologically acceptable salts 0001) The invention relates to a combination preparation thereof and at least one antiangiogenically and/or cytotoxi of 2-methylthiazolidine-2,4-dicarboxylic acid and/or physi cally and/or cytostatically active compound. ologically acceptable salts thereof and of at least one anti 0011) 2-Methylthiazolidine-2,4-dicarboxylic acid is a angiogenic cytotoxic and/or cytostatic compound. The chemical compound with two stereogenic centers wherein invention relates further to the use of these combination the R-configuration at position 4 is especially preferred. The preparations for the treatment of cancer as well as to the Stereogenic centre at position 2 has no preferred configura increase of the efficacy of antiangiogenic and/or cytotoxic t1On. and/or cytostatic compounds by the additional administra tion of 2-methylthiazolidine-2,4-dicarboxylic acid. 0012. The term “2-methylthiazolidine-2,4-dicarboxylic acid is supposed to refer to the diastereomeric compounds 0002 The synthesis of 2-methylthiazolidine-2,4-dicar (2R-4R)-2-methylthiazolidine-2,4-dicarboxylic acid, (2S, boxylic acid is well known from DE-OS 21 16629. EPO 969 4R)-2-methylthiazolidine-2,4-dicarboxylic acid as well as 834 B1 discloses the use of 2-methylthiazolidine-2,4-dicar (2RS.4R)-2-methyl-thiazolidine-2,4-dicarboxylic acid. In boxylic acid as mucolytic agent, EP 98 916 809 describes a the case of (2RS.4R)-2-methylthiazolidine-2,4-dicarboxylic combination preparation of 2-methylthiazolidine-2,4-dicar acid, the molar ratio of (2R,4R)-2-methylthiazolidine-2,4- boxylic acid and paracetamol, and EP 01915 023 discusses dicarboxylic acid to (2S,4R)-2-methylthiazolidine-2,4-di the use of 2-methylthiazolidine-2,4-dicarboxylic acid for the carboxylic acid can range from 90:10 to 10:90, wherein the treatment of infective diseases, especially HIV. percentages of (2R.4R)-2-methylthiazolidine-2,4-dicar 0003 European patent EP 1255 538 B1 discloses the use boxylic acid preferably prevails. of 2-methylthiazolidine-2,4-dicarboxylic acid for the treat 0013 Furthermore, the term “2-methylthiazolidine-2,4- ment and prophylaxis of cancer. In this patent the use of dicarboxylic acid” is supposed to comprise not only the free 2-methylthiazolidine-2,4-dicarboxylic acid for the prepara acid but also physiologically acceptable salts. Accordingly, tion of a drug for prevention and/or reduction of undesired the compound 2-methylthiazolidine-2,4-dicarboxylic acid side effects of cytostatics is also described. and respectively an enantiomer, diastereomer or an enantio 0004 Cytostatics represent substances which prevent or meric and/or diastereomeric mixture thereof can be admin considerably delay the initiation and interrupt or respec istered as free acid and/or in form of the pharmacologically tively disturb the cycle of the nuclear and/or plasma division acceptable salt. Suitable examples of these salts comprise (karyokinesis or respectively cytokinesis). They interfere acid addition salts and alkaline metal salts. Thus, alkaline either with the reduplication or the transcription of the DNA metal salts can be used, such as the sodium salt, the or with the formation and disjunction of its carrier structures potassium salt, the lithium salt, the magnesium salt, the and lead to division perturbing chromosome aberrations or calcium salt and/or alkyl ammonium salts. As acids which respectively suppress the formation and disturb the function form an acid addition salt the following ones can be men of the spindle apparatus (and are almost always mutage tioned: Sulphuric acid, Sulphonic acid, phosphoric acid, neous). In the broader sense, cytostatics also represent nitric acid, nitrous acid, perchloric acid, hydrobromic acid, Substances which respectively disturb and prevent the pro hydrochloric acid, formic acid, acetic acid, propionic acid, Vision of the necessary energy for the nucleoprotein synthe Succinic acid, oxalic acid, gluconic acid (glyconic acid, sis or the spindle function. Generally, they are classified into dextronic acid), lactic acid, malic acid, tartaric acid, tartronic antimetabolites, alkylating agents, cytostatically active anti acid (hydroxymalonic acid, hydroxypropionic diacid), biotics and mitosis inhibitors according to their mode of fumaric acid, citric acid, ascorbic acid, maleic acid, malonic action (Roche Lexikon Medizin, 4. Edition; (C) Urban & acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, Fischer Verlag, Munchen 1984/1987/1993/1999). (o, m, p)-toluic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, salicylic acid, p-aminosalicylic 0005) Paclitaxel (TaxolR) is probably one of the best acid, methanesulfonic acid, ethanesulfonic acid, hydroxy investigated cytostatics. ethanesulfonic acid, ethylenesulfonic acid, p-toluene 0006 EP 1255 538 B1 discloses the use of 2-methylthi Sulfonic acid, naphthylsulfonic acid, naphthylamine sulfonic azolidine-2,4-dicarboxylic acid for the reduction of undes acid, Sulfanilic acid, camphersulfonic acid, china acid ired side effects of cytostatics. Thus, EP 1255 538 B1 gives (canine acid), o-methylmandelic acid, hydrogen-benzene a solution for the problem of reducing undesired side effects Sulfonic acid, picric acid (2,4,6-trinitrophenol), adipic acid, of cytostatics. and D-o-tolyltartaric acid. Amino acids can also be used for the salt formation such as glycine, alanine, valine, leucine, 0007 The object of the present invention, however, is to isoleucine, serine, threonine, phenylalanine, tyrosine, tryp increase the effect, i.e. the efficacy and/or activity of cyto tophan, lysine, arginine, histidine, aspartic acid, glutamic statics. acid, asparagine, glutamine, cysteine, methionine and pro 0008. This object is solved by the technical teaching of line wherein the amino acids methionine, tryptophan, lysine the independent patent claims. Advantageous embodiments and arginine are preferred. of the invention are given in the dependent patent claims, the 0014) A combination preparation which contains 2-me description as well as in the examples. thylthiazolidine-2,4-dicarboxylic acid, i.e. at least one enan 0009 Surprisingly, it was shown that the above described tiomer or a diastereomer of 2-methylthiazolidine-2,4-dicar effect of cytostatics can be increased by administration of boxylic acid as free acid or as salt and at least one 2-methylthiazolidine-2,4-dicarboxylic acid. antiangiogenic and/or at least one cytotoxic compound and/ US 2007/0213382 A1 Sep. 13, 2007 or at least a cytostatic compound does not have to contain mycin, Cerubidine), doxorubicin (adriamycin) as well as obligatorily both active agents in one pharmaceutical for liposomaladriamycin, dactinomycin, mitomycin C, bleomy mulation. cin (Blenoxane), epirubicin (4-epi-adriamycin), idarubicin 0015. Obviously, pharmaceutical formulations can be (Idamycin), dactinomycin (Actinomycin D. Cosmegen), provided which contain 2-methylthiazolidine-2,4-dicar mitoxantrone (Novantrone), mitomycin C (Mitomycin), Pli boxylic acid together with the antiangiogenic and/or cyto camycin (Mithracin), amsacrine and actinomycin D. toxic and/or cytostatic compound. The preferred prepara 0021 Methotrexate (MTX, Mexate), 5-fluorouracil tions, however, are combination preparations which (Fluoracil, 5-FU), 6-thioguanine (Thioguanine, 6-TG), comprise two separate pharmaceutical formulations, namely 6-mercaptopurine, fludarabine (Fludara), floxuridine one for 2-methylthiazolidine-2,4-dicarboxylic acid and (FUDR), cladribine, pentostatin, gemcitabine (Gemzar), cyt another one for the at least one antiangiogenic and/ or arabine, azathioprine, raltitrexed, capecitabine (Xeloda), cytotoxic and/or cytostatic compound. This is advantageous cytosine arabinoside, deoxycoformycin (Pentostatin, since both active agents can
Load more

Recommended publications
  • Miltefosine Combined with Intralesional Pentamidine for Leishmania Braziliensis Cutaneous Leishmaniasis in Bolivia
    Am. J. Trop. Med. Hyg., 99(5), 2018, pp. 1153–1155 doi:10.4269/ajtmh.18-0183 Copyright © 2018 by The American Society of Tropical Medicine and Hygiene Miltefosine Combined with Intralesional Pentamidine for Leishmania braziliensis Cutaneous Leishmaniasis in Bolivia Jaime Soto,1* Paula Soto,1 Andrea Ajata,2 Daniela Rivero,3 Carmelo Luque,2 Carlos Tintaya,2 and Jonathan Berman4 1FUNDERMA (Fundacion ´ Nacional de Dermatolog´ıa), Santa Cruz, Bolivia; 2Servicio Departamental de Salud, Departamento de La Paz, La Paz, Bolivia; 3Hospital Dermatologico ´ de Jorochito, Santa Cruz, Bolivia; 4AB Foundation, North Bethesda, Maryland Abstract. Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of mil- tefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 μg/mm2 lesion area on days 1, 3, and 5). Ninety-two per cent of 50 patients cured. Comparison to historic controls at our site suggests that the efficacy of the two drugs was additive. Adverse effects and cost were also additive. This combination may be attractive when a prime consideration is efficacy (e.g., in rescue therapy), avoidance of parenteral therapy, or the desire to treat locally and also provide systemic protection against parasite dissemination. INTRODUCTION METHODS AND PATIENTS Cutaneous leishmaniasis (CL) in the New World gener- Study design and treatments. This was an open-label ally presents as a papule that enlarges and ulcerates over evaluation of one intervention: standard treatment with oral 1–3 months and then self-cures, but the predominant spe- miltefosine in combination with intralesional treatment with cies at our site in Bolivia, Leishmania (Viannia) braziliensis pentamidine.
    [Show full text]
  • 204684Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204684Orig1s000 OFFICE DIRECTOR MEMO Deputy Office Director Decisional Memo Page 2 of 17 NDA 204,684 Miltefosine Capsules 1. Introduction Leishmania organisms are intracellular protozoan parasites that are transmitted to a mammalian host by the bite of the female phlebotomine sandfly. The main clinical syndromes are visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucosal leishmaniasis (ML). VL is the result of systemic infection and is progressive over months or years. Clinical manifestations include fever, hepatomegaly, splenomegaly, and bone marrow involvement with pancytopenia. VL is fatal if untreated. Liposomal amphotericin B (AmBisome®) was FDA approved in 1997 for the treatment of VL. CL usually presents as one or more skin ulcers at the site of the sandfly bite. In most cases, the ulcer spontaneously resolves within several months, leaving a scar. The goals of therapy are to accelerate healing, decrease morbidity and decrease the risk of relapse, local dissemination, or mucosal dissemination. There are no FDA approved drugs for the treatment of CL. Rarely, CL disseminates from the skin to the naso-oropharyngeal mucosa, resulting in ML. ML can also develop some time after CL spontaneous ulcer healing. The risk of ML is thought to be highest with CL caused by the subgenus Viannia. ML is characterized in the medical literature as progressive with destruction of nasal and pharyngeal structures, and death may occur due to complicating aspiration pneumonia. There are no FDA approved drugs for the treatment of ML. Paladin Therapeutics submitted NDA 204, 684 seeking approval of miltefosine for the treatment of VL caused by L.
    [Show full text]
  • Natural Products That Target the Arginase in Leishmania Parasites Hold Therapeutic Promise
    microorganisms Review Natural Products That Target the Arginase in Leishmania Parasites Hold Therapeutic Promise Nicola S. Carter, Brendan D. Stamper , Fawzy Elbarbry , Vince Nguyen, Samuel Lopez, Yumena Kawasaki , Reyhaneh Poormohamadian and Sigrid C. Roberts * School of Pharmacy, Pacific University, Hillsboro, OR 97123, USA; cartern@pacificu.edu (N.S.C.); stamperb@pacificu.edu (B.D.S.); fawzy.elbarbry@pacificu.edu (F.E.); nguy6477@pacificu.edu (V.N.); lope3056@pacificu.edu (S.L.); kawa4755@pacificu.edu (Y.K.); poor1405@pacificu.edu (R.P.) * Correspondence: sroberts@pacificu.edu; Tel.: +1-503-352-7289 Abstract: Parasites of the genus Leishmania cause a variety of devastating and often fatal diseases in humans worldwide. Because a vaccine is not available and the currently small number of existing drugs are less than ideal due to lack of specificity and emerging drug resistance, the need for new therapeutic strategies is urgent. Natural products and their derivatives are being used and explored as therapeutics and interest in developing such products as antileishmanials is high. The enzyme arginase, the first enzyme of the polyamine biosynthetic pathway in Leishmania, has emerged as a potential therapeutic target. The flavonols quercetin and fisetin, green tea flavanols such as catechin (C), epicatechin (EC), epicatechin gallate (ECG), and epigallocatechin-3-gallate (EGCG), and cinnamic acid derivates such as caffeic acid inhibit the leishmanial enzyme and modulate the host’s immune response toward parasite defense while showing little toxicity to the host. Quercetin, EGCG, gallic acid, caffeic acid, and rosmarinic acid have proven to be effective against Leishmania Citation: Carter, N.S.; Stamper, B.D.; in rodent infectivity studies.
    [Show full text]
  • The Epidemiology and Clinical Features of Balamuthia Mandrillaris Disease in the United States, 1974 – 2016
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Clin Infect Manuscript Author Dis. Author manuscript; Manuscript Author available in PMC 2020 August 28. Published in final edited form as: Clin Infect Dis. 2019 May 17; 68(11): 1815–1822. doi:10.1093/cid/ciy813. The Epidemiology and Clinical Features of Balamuthia mandrillaris Disease in the United States, 1974 – 2016 Jennifer R. Cope1, Janet Landa1,2, Hannah Nethercut1,3, Sarah A. Collier1, Carol Glaser4, Melanie Moser5, Raghuveer Puttagunta1, Jonathan S. Yoder1, Ibne K. Ali1, Sharon L. Roy6 1Waterborne Disease Prevention Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA 2James A. Ferguson Emerging Infectious Diseases Fellowship Program, Baltimore, MD, USA 3Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA 4Kaiser Permanente, San Francisco, CA, USA 5Office of Financial Resources, Centers for Disease Control and Prevention Atlanta, GA, USA 6Parasitic Diseases Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA Abstract Background—Balamuthia mandrillaris is a free-living ameba that causes rare, nearly always fatal disease in humans and animals worldwide. B. mandrillaris has been isolated from soil, dust, and water. Initial entry of Balamuthia into the body is likely via the skin or lungs. To date, only individual case reports and small case series have been published. Methods—The Centers for Disease Control and Prevention (CDC) maintains a free-living ameba (FLA) registry and laboratory. To be entered into the registry, a Balamuthia case must be laboratory-confirmed.
    [Show full text]
  • Relevance Network Between Chemosensitivity and Transcriptome in Human Hepatoma Cells1
    Vol. 2, 199–205, February 2003 Molecular Cancer Therapeutics 199 Relevance Network between Chemosensitivity and Transcriptome in Human Hepatoma Cells1 Masaru Moriyama,2 Yujin Hoshida, topoisomerase II ␤ expression, whereas it negatively Motoyuki Otsuka, ShinIchiro Nishimura, Naoya Kato, correlated with expression of carboxypeptidases A3 Tadashi Goto, Hiroyoshi Taniguchi, and Z. Response to nimustine was associated with Yasushi Shiratori, Naohiko Seki, and Masao Omata expression of superoxide dismutase 2. Department of Gastroenterology, Graduate School of Medicine, Relevance networks identified several negative University of Tokyo, Tokyo 113-8655 [M. M., Y. H., M. O., N. K., T. G., H. T., Y. S., M. O.]; Cellular Informatics Team, Computational Biology correlations between gene expression and resistance, Research Center, Tokyo 135-0064 [S. N.]; and Department of which were missed by hierarchical clustering. Our Functional Genomics, Graduate School of Medicine, Chiba University, results suggested the necessity of systematically Chiba 260-8670 [N. S.], Japan evaluating the transporting systems that may play a major role in resistance in hepatoma. This may provide Abstract useful information to modify anticancer drug action in Generally, hepatoma is not a chemosensitive tumor, hepatoma. and the mechanism of resistance to anticancer drugs is not fully elucidated. We aimed to comprehensively Introduction evaluate the relationship between chemosensitivity and Hepatoma is a major cause of death even in developed gene expression profile in human hepatoma cells, by countries, and its incidence is increasing (1). Despite the using microarray analysis, and analyze the data by progress of therapeutic technique (2), the efficacy of radical constructing relevance networks. therapy is hampered by frequent recurrence and advance of In eight hepatoma cell lines (HLE, HLF, Huh7, Hep3B, the tumor (3).
    [Show full text]
  • Title Second-Line Chemotherapy for Small-Cell Lung Cancer
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Kyoto University Research Information Repository Second-line chemotherapy for small-Cell Lung Cancer Title (SCLC). Author(s) Kim, Young Hak; Mishima, Michiaki Citation Cancer treatment reviews (2011), 37(2): 143-150 Issue Date 2011-04 URL http://hdl.handle.net/2433/137220 Right © 2010 Elsevier Ltd Type Journal Article Textversion author Kyoto University Second-line Chemotherapy for Small-Cell Lung Cancer (SCLC) Young Hak Kim and Michiaki Mishima Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan For reprints and all correspondence: Young Hak Kim Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan Phone: +81-75-751-3830; Fax: +81-75-751-4643; E-mail: [email protected] Running title: Second-line Chemotherapy for SCLC Key words: small-cell lung cancer, relapsed, chemotherapy, second line, sensitive, refractory 1 Abstract Although small-cell lung cancer (SCLC) generally shows an excellent response to initial chemotherapy, most patients finally relapse and salvage chemotherapy is considered. Usually, the response to salvage chemotherapy significantly differs between sensitive and refractory relapse. Sensitive relapse is relatively chemosensitive and re-challenge with the same drugs as used in the initial chemotherapy has been used historically, while refractory relapse is extremely chemoresistant and its prognosis has been abysmal. To date, a number of clinical trials have been carried out for relapsed SCLC; however, the number of randomized trials is quite limited.
    [Show full text]
  • Epigallocathechin-O-3-Gallate Inhibits Trypanothione Reductase of Leishmania Infantum, Causing Alterations in Redox Balance And
    ORIGINAL RESEARCH published: 25 March 2021 doi: 10.3389/fcimb.2021.640561 Epigallocathechin-O-3-Gallate Inhibits Trypanothione Reductase of Leishmania infantum, Causing Alterations in Redox Balance and Edited by: Leading to Parasite Death Brice Rotureau, Institut Pasteur, France Job D. F. Inacio 1, Myslene S. Fonseca 1, Gabriel Limaverde-Sousa 2, Ana M. Tomas 3,4, Reviewed by: Helena Castro 3 and Elmo E. Almeida-Amaral 1* Wanderley De Souza, Federal University of Rio de Janeiro, 1 Laborato´ rio de Bioqu´ımica de Tripanosomatideos, Instituto Oswaldo Cruz (IOC), Fundac¸ão Oswaldo Cruz – FIOCRUZ, Brazil Rio de Janeiro, Brazil, 2 Laborato´ rio de Esquistossomose Experimental, Instituto Osvaldo Cruz, Fundac¸ão Oswaldo Cruz – Andrea Ilari, FIOCRUZ, Rio de Janeiro, Brazil, 3 i3S—Instituto de Investigac¸ão e Inovac¸ão em Sau´ de, Universidade do Porto, Porto, Italian National Research Portugal, 4 ICBAS—Instituto de Cieˆ ncias Biome´ dicas Abel Salazar, Universidade do Porto, Porto, Portugal Council, Italy Marina Gramiccia, ISS, Italy Leishmania infantum is a protozoan parasite that causes a vector borne infectious disease *Correspondence: in humans known as visceral leishmaniasis (VL). This pathology, also caused by L. Elmo E. Almeida-Amaral donovani, presently impacts the health of 500,000 people worldwide, and is treated elmo@ioc.fiocruz.br with outdated anti-parasitic drugs that suffer from poor treatment regimens, severe side Specialty section: effects, high cost and/or emergence of resistant parasites. In previous works we have This article was submitted to disclosed the anti-Leishmania activity of (-)-Epigallocatechin 3-O-gallate (EGCG), a Parasite and Host, flavonoid compound present in green tea leaves.
    [Show full text]
  • Treatment of Visceral Leishmaniasis with Intravenous Pentamidine And
    International Journal of Infectious Diseases 14 (2010) e522–e525 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: www.elsevier.com/locate/ijid Case Report Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure — a case report and brief review of the literature Jan Rybniker a, Valentin Goede a, Jessica Mertens b, Monika Ortmann c, Wolfgang Kulas d, Matthias Kochanek a, Thomas Benzing e, Jose´ R. Arribas f, Gerd Fa¨tkenheuer a,* a 1st Department of Internal Medicine, University of Cologne, 50924 Cologne, Germany b Department of Gastroenterology, University of Cologne, Cologne, Germany c Institute of Pathology, University of Cologne, Cologne, Germany d Nephrologisches Zentrum Mettmann, Mettmann, Germany e Department of Medicine and Centre for Molecular Medicine, University of Cologne, Cologne, Germany f Enfermedades Infecciosas, Hospital Universitario La Paz, Madrid, Spain ARTICLE INFO SUMMARY Article history: We report the case of an HIV-positive patient with visceral leishmaniasis and several relapses after Received 3 March 2009 treatment with the two first-line anti-leishmanial drugs, liposomal amphotericin B and miltefosine. End- Accepted 4 June 2009 stage renal failure occurred in 2007 when the patient was on long-term treatment with miltefosine. A Corresponding Editor: William Cameron, relapse of leishmaniasis in 2008 was successfully treated with a novel combination regimen of Ottawa, Canada intravenous pentamidine and oral fluconazole. Secondary prophylaxis with fluconazole monotherapy did not prevent parasitological relapse of leishmaniasis. Keywords: ß 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Visceral leishmaniasis HIV Fluconazole Pentamidine Miltefosine Renal failure 1.
    [Show full text]
  • Nimustine Induces DNA Breaks and Crosslinks in NIH/3T3 Cells
    International Journal of Bioscience, Biochemistry and Bioinformatics, Vol. 3, No. 3, May 2013 Nimustine Induces DNA Breaks and Crosslinks in NIH/3T3 Cells Lin-Na Zhao, Xue-Chai Chen, Yan-Yan Zhong, Qin-Xia Hou, and Ru-Gang Zhong study of drug-induced DNA cross-linking to reveal the Abstract—The relationship between carcinogenicity and difference between the nitrosourea anticancer mechanism DNA interstrand cross-links of nitrosoureas is poorly defined. and carcinogenic role. 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3- (2-chloroethyl)- ACNU was discovered in 1974 as the first water-soluble 3- nitrosourea (ACNU, nimustine) is one of nitrosoureas used in nitrosourea compound [11], and mainly used in the clinic of the treatment of high-grade gliomas. It has the capability of causing DNA interstrand cross-links (ICLs) to kill cancer cells. glioblastoma patients before the introduction of But it can also cause the generation of secondary tumors with 8-carbamoyl-3-methylimidazo [5, 1-d]-1, 2, 3, carcinogenic side effects. In present study, we investigated DNA 5-tetrazin-4(3H) -one (temozolomide, TMZ) because of its interstrand cross-links, DNA double-strand breaks and cell high permeability across blood-brain barrier (BBB) and good cycle phase in NIH/3T3 cells from the primary mouse cytotoxic activity for gliomas [12]-[13]. BCNU always embryonic fibroblast cells induced by ACNU. This result induces two major types of genotoxic damage to the cell: indicated that the concentration of 60 and 75μg/ml of ACNU could be detected significantly ICLs, and the γ-H2AX has the DNA mono adducts and DNA interstrand cross-links.
    [Show full text]
  • Lopinavir, an HIV-1 Peptidase Inhibitor, Induces Alteration on the Lipid Metabolism of Cambridge.Org/Par Leishmania Amazonensis Promastigotes
    Parasitology Lopinavir, an HIV-1 peptidase inhibitor, induces alteration on the lipid metabolism of cambridge.org/par Leishmania amazonensis promastigotes 1 2 3 Special Issue Research Karina M. Rebello , Valter V. Andrade-Neto , Aline A. Zuma , 3 4 Article Maria Cristina M. Motta , Claudia Regina B. Gomes , Marcus Vinícius N. de Souza4, Geórgia C. Atella5, Marta H. Branquinha6, ‡Both authors share senior authorship. André L. S. Santos6, Eduardo Caio Torres-Santos2,‡ and Claudia M. d’Avila-Levy1,‡ Cite this article: Rebello KM et al (2018). Lopinavir, an HIV-1 peptidase inhibitor, 1Laboratório de Estudos Integrados em Protozoologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz induces alteration on the lipid metabolism of (FIOCRUZ), Rio de Janeiro, Brazil; 2Laboratório de Bioquímica de Tripanosomatídeos, Instituto Oswaldo Cruz, Leishmania amazonensis promastigotes. 3 145 – FIOCRUZ, Rio de Janeiro, Brazil; Laboratório de Ultraestrutura Celular Hertha Meyer, Instituto de Biofísica Carlos Parasitology , 1304 1310. https://doi.org/ 4 10.1017/S0031182018000823 Chagas Filho, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil; Laboratório de Síntese de Fármacos, Farmanguinhos, FIOCRUZ, Rio de Janeiro, Brazil; 5Instituto de Bioquímica Médica, UFRJ, Rio de Received: 8 February 2018 Janeiro, Brazil and 6Laboratório de Investigação de Peptidases, Instituto de Microbiologia Paulo de Góes, UFRJ, Revised: 3 April 2018 Rio de Janeiro, Brazil Accepted: 5 April 2018 First published online: 28 May 2018 Key words: Abstract Aspartyl; chemotherapy; co-infection; The anti-leishmania effects of HIV peptidase inhibitors (PIs) have been widely reported; how- leishmaniasis; trypanosomatids ever, the biochemical target and mode of action are still a matter of controversy in Leishmania Author for correspondence: parasites.
    [Show full text]
  • Nanoconjugates Able to Cross the Blood-Brain Barrier Alexander H Stegh, Janina Paula Luciano, Samuel A
    (12) STANDARD PATENT (11) Application No. AU 2017216461 B2 (19) AUSTRALIAN PATENT OFFICE (54) Title Nanoconjugates Able To Cross The Blood-Brain Barrier (51) International Patent Classification(s) A61K 31/7088 (2006.01) A61K 48/00 (2006.0 1) A61K 9/00 (2006.01) A61P 35/00 (2006.01) (21) Application No: 2017216461 (22) Date of Filing: 2017.08.15 (43) Publication Date: 2017.08.31 (43) Publication Journal Date: 2017.08.31 (44) Accepted Journal Date: 2019.10.17 (62) Divisional of: 2012308302 (71) Applicant(s) NorthwesternUniversity (72) Inventor(s) Mirkin, Chad A.;Ko, Caroline H.;Stegh, Alexander;Giljohann, David A.;Luciano, Janina;Jensen, Sam (74) Agent / Attorney WRAYS PTY LTD, L7 863 Hay St, Perth, WA, 6000, AU (56) Related Art US 2010/0233084 Al LJUBIMOVA et al. "Nanoconjugate based on polymalic acid for tumor targeting", Chemico-Biological Interactions, 2008, Vol. 171, Pages 195-203. WO 2011/028847 Al BONOU et al. "Nanotechnology approach for drug addiction therapy: Gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons", PNAS, 2009, Vol. 106, No. 14, Pages 5546-5550. PATIL et al. "Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Poly(#-L-malic acid)", Pharmaceutical Research, 2010, Vol. 27, Pages 2317-2329. ABSTRACT Polyvalent nanoconjugates address the critical challenges in therapeutic use. The single-entity, targeted therapeutic is able to cross the blood-brain barrier (BBB) and is thus effective in the treatment of central nervous system (CNS) disorders. Further, despite the tremendously high 5 cellular uptake of nanoconjugates, they exhibit no toxicity in the cell types tested thus far.
    [Show full text]
  • Interactions with Protease Inhibitors Charts Revised February 2018
    www.hiv-druginteractions.org Interactions with Protease Inhibitors Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 1 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ATV Cobi DRV FPV IDV LPV RTV SQV TPV ATV Cobi DRV FPV IDV LPV RTV SQV TPV Anaesthetics & Muscle Relaxants Antibacterials (continued) Alcuronium Ertapenem Bupivacaine Erythromycin Cisatracurium Ethambutol Desflurane Ethionamide Dexmedetomidine Flucloxacillin Enflurane Gentamicin Ephedrine Imipenem/Cilastatin Halothane Isoniazid Isoflurane Kanamycin Ketamine Levofloxacin Linezolid Nitrous oxide Meropenem Propofol Metronidazole Rocuronium Moxifloxacin Sevoflurane Nitrofurantoin Sufentanil Ofloxacin Suxamethonium (succinylcholine) Para-aminosalicylic acid Tetracaine Penicillins Thiopental for distribution. for Pyrazinamide Tizanidine Rifabutin Vecuronium Rifampicin Analgesics Rifapentine Alfentanil Rifaximin Aspirin Spectinomycin Buprenorphine Streptomycin Celecoxib Sulfadiazine Codeine Telithromycin Tetracyclines
    [Show full text]